This fusion is more commonly described in lung cancer and results in constitutive ALK activation leading to cell proliferation and tumorigenesis [48]. EML4-ALK has also been found to be a potent oncogenic activator in cell lines and genetically engineered mouse models [49]. This evidence concerns the gene ALK and lung cancer.